Seizure management in the setting of hepatic disease

Current Treatment Options in Neurology

Volumn 13, Issue 4, 2011, Pages 333-345

  Boggs, Jane G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLORAZEPATE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; RUFINAMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABDOMINAL PAIN; ACUTE HEPATITIS; ALOPECIA; ANOREXIA; ARTICLE; ATAXIA; BLOOD DYSCRASIA; BRAIN DEPTH STIMULATION; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD CARE; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRESS SYNDROME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; HEADACHE; HEART FAILURE; HUMAN; HYPERAMMONEMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; IRRITABILITY; LIFESTYLE MODIFICATION; LIVER DISEASE; LIVER FAILURE; LIVER TOXICITY; MOOD DISORDER; MULTIPLE ORGAN FAILURE; MUSCLE TONE; NAUSEA; NEUROLOGIC EXAMINATION; NEUROSURGERY; NEUROTOXICITY; NYSTAGMUS; PARESTHESIA; PERIPHERAL EDEMA; PORPHYRIA CUTANEA TARDA; PR INTERVAL; RASH; RESPIRATION DEPRESSION; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREMOR; VISUAL ACUITY; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 80051671994     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-011-0129-6     Document Type: Article

References (35)

1. S Ingleman 2004 M: Pharmacogenetics of cytochrome P450 and its application in drug therapy: the past, the present and the future Trends Pharmacol Sci 25 4 193 200 10.1016/j.tips.2004.02.007 (Pubitemid 38519910)
2. Garnett WR. Gastrointestinal and hepatic disease. In: Ettinger AB, Devinsky O, editors. Managing epilepsy and co-existing disorders. Woburn: Butterworth-Heinemann; 2002. p. 63-74.
3. G Lacerda T Krummel C Sabourdy, et al. 2006 Optimizing therapy of seizures in patients with renal or hepatic dysfunction Neurology 67 Suppl 4 S28 S83 17190918 1:CAS:528:DC%2BD28XhtlagsbzJ
4. HA Wynne LH Cope E Mutch, et al. 1989 The effect of age upon liver volume and apparent liver blood flow in healthy men Hepatology 9 2 297 301 2643548 10.1002/hep.1840090222 1:STN:280:DyaL1M7gvVejuw%3D%3D (Pubitemid 19063317)
5. K Ballaban-Gil C Callahan C O'Dell, et al. 1998 Complications of the ketogenic diet Epilepsia 39 744 748 9670903 10.1111/j.1528-1157.1998.tb01160.x 1:STN:280:DyaK1czjtl2kug%3D%3D (Pubitemid 28319511)
6. Smith M, Politzer N, Macgarvie D, et al. Efficacy and tolerability of the Modified Atkins Diet in adults with pharmacoresistant epilepsy: A prospective observational study. Epilepsia 2011 Jan 26 (Epub ahead of print). doi: 10.1111/j.1528-1167.2010.02941.x. This article is of special interest, as it indicates that palatable dietary modification of varying degrees can have ameliorating effects on epilepsy. Previous literature has shown efficacy of ketogenic diets for refractory epilepsy, but its use is limited to those who can tolerate the loss of pleasing flavors and components of usual dietary fare.
7. Anderson GD, Levy RH. Phenobarbital: Chemistry and Biotransformation. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven; 1995. p. 379-87.
8. US Prescribing Information, available at http://www.pdr.net/drugpages/ productlabelinglist.aspx.
9. Drug Options Red Book. Montvale NJ: Medical Economics; 2010.
10. SK Tate C Depondt SM Sisodiya, et al. 2005 Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin Proc Natl Acad Sci U S A. 102 15 5507 5512 15805193 10.1073/pnas.0407346102 1:CAS:528:DC%2BD2MXjslaqtro%3D (Pubitemid 40530288)
11. TR Aweeka MD Gottwald JG Gambertoglio, et al. 1999 Pharmacokinetics of fosphenytoin with hepatic or renal disease Epilepsia 40 6 777 782 10368078 10.1111/j.1528-1157.1999.tb00778.x 1:CAS:528:DyaK1MXmt1Sjtb4%3D (Pubitemid 29260719)
12. Hidvegi T, Ewing M, Hale P, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010, 329(5988):229-32. This article is of interest, as much of the previous literature relating to carbamazepine and the liver has not demonstrated any positive effects of this chemical. Use of carbamazepine for its cellular effects appears to be promising and may suggest that other AEDS could have heretofore-undescribed beneficial properties in other disease states.
13. Guerriero CAM, Guerriero MM. Carbamazepine and oxcarbazepine. In: Wyllie E, editor. The treatment of epilepsy. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 614-21.
14. Baillie TA, Sheffels PR. Valproic acid: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven; 1995. p. 605-19.
15. BE Gidal CM Inglese JE Meyer, et al. 1997 Diet and valproate-induced transient hyperammonemia: effect of L-carnitine Pediatr Neurol. 16 301 305 9258962 10.1016/S0887-8994(97)00026-X 1:STN:280:DyaK2svgtlKjtA%3D%3D (Pubitemid 27329935)
16. Kanner AM, Glauser TA, Morita DA. Ethosuximide. In: Wyllie E, editor. The treatment of epilepsy. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 657-67.
17. Greenfield Jr LJ, Rosenberg HC, Tietz E. Benzodiazepines. In: Wyllie E, editor. The treatment of epilepsy. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 668-89.
18. JJ Asconape JK Penry 1982 Use of antiepileptic drugs in the presence of liver and kidney disease: a review Epilepsia 23 suppl 1 565 579
19. Gilliam F, Gidal BE. Lamotrigine. In: Wyllie E, editor. The treatment of epilepsy. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 704-9.
20. M Bialer SI Johannessen HJ Kupferberg, et al. 1999 Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV) Epilepsy Res 34 1 41 10194110 10.1016/S0920-1211(98)00108-9 1:CAS:528: DyaK1MXitlOnsL8%3D (Pubitemid 29130316)
21. MF Amante AV Filippini N Cejas, et al. 2009 DRESS syndrome and fulminant hepatic failure induced by lamotrigine Ann Hepatol. 8 1 75 7 19221540 1:CAS:528:DC%2BD1MXitlKju78%3D
22. WO Tatum 4th SB Zachariah 1995 Gabapentin treatment of seizures in acute intermittent porphyria Neurology 45 6 1216 7 7783893
23. MCClean MJ, Gidal BE. Gabapentin and pregabalin. In: Wyllie E, editor. The treatment of epilepsy. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 690-703.
24. SC Nallani TA Glauser N Hariparsad, et al. 2003 Dose dependent induction of cytochrome P450 (CYP3A4) and activation of pregnane X receptor by topiramate Epilepsia 44 1521 1528 14636322 10.1111/j.0013-9580.2003.06203.x 1:CAS:528:DC%2BD2cXmtF2nsw%3D%3D (Pubitemid 38020186)
25. WR Garnett 2002 Clinical pharmacology of topiramate: a review Epilepsia 41 suppl 1 S61 S65
26. Welty TE. Zonisamide. In: Wyllie E, editor. The treatment of epilepsy. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 723-30.
27. PN Patsalos 2000 Pharmacokinetic profile of levetiracetam: toward ideal characteristics Pharmacol Ther 85 77 85 10722121 10.1016/S0163-7258(99)00052-2 1:CAS:528:DC%2BD3cXosFSnsA%3D%3D (Pubitemid 30069478)
28. AN Edginton S Willmann 2008 Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis Clin Pharmacokinet 47 11 743 52 18840029 10.2165/00003088-200847110- 00005
29. BA Bopp GE Nequist AD Rodrigues 1995 Role of the cytochrome P450 3A subfamily in the metabolism of (14 C) tiagabine by human hepatic microsomes Epilepsia 36 suppl 3 S159
30. AH Lau LE Gustavson R Sperelakis, et al. 1997 Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function Epilepsia. 38 4 445 51 9118850 10.1111/j.1528-1157.1997.tb01734.x 1:CAS:528: DyaK2sXislCqu7c%3D (Pubitemid 27172025)
31. JM Wild C Martinez G Reinshagen, et al. 1999 Characteristics of a unique visual field defect attributed to vigabatrin Epilepsia 40 12 1784 1794 10612345 10.1111/j.1528-1157.1999.tb01599.x 1:STN:280:DC%2BD3c%2FnslGqsA%3D%3D
32. E Perucca J Cloyd D Critchley, et al. 2008 Rufinamide clinical pharmacokinetics and concentration-response relationships in patients with epilepsy Epilepsia 49 7 1123 1141 18503564 10.1111/j.1528-1167.2008.01665.x 1:CAS:528:DC%2BD1cXpslWmtLw%3D (Pubitemid 351991401)
33. Boggs JG, Waterhouse E, DeLorenzo RJ: Lacosamide. In Wyllie E, editor. The Treatment of Epilepsy, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011: 576-591. This reference is the most recent comprehensive review of this topic.
34. RC Sachdeo SK Narang-Sachdeo RC Shumaker, et al. 1997 Tolerability and pharmacokinetics of monotherapy felbamate doses of 1200-6000 mg/day in subjects with epilepsy Epilepsia 38 887 892 9579889 10.1111/j.1528-1157.1997.tb01253.x 1:CAS:528:DyaK2sXls1Wlur8%3D (Pubitemid 27323597)
35. JM Pellock MJ Brodie 1997 Felbamate: 1997 update Epilepsia 38 1261 1264 9578519 10.1111/j.1528-1157.1997.tb00061.x 1:STN:280:DyaK1c3jslKgsw%3D%3D (Pubitemid 28007513)